-
Nov 11, 2024 | 
onlinelibrary.wiley.com | Jessica Fairley |Samar Ojaimi |Eric F. Morand |Janelle See
Corresponding Author Jessica L. Fairley Department of Rheumatology, Monash Health, Melbourne, Victoria, Australia Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia Correspondence Jessica Fairley, Department of Rheumatology, Monash Medical Centre, 246 Clayton Road, Melbourne, Vic. 3168, Australia. Email: [email protected] for more papers by this author
-
Jul 25, 2024 | 
dev.to | Eric F. Morand
Let me present you today a whole new code coverage tool, aiming at accuracy, simplicity, flexibility and speed, named One Double Zero. Why another code coverage utility? Fair enough: both nyc and c8 are widely used tools, so why would we need another code coverage utility? The short answer is: because none of them is satisfying. For the long answer, let's start by establishing what a good code coverate tool should be, and, then, let's see how nyc, c8 and One Double Zero compare to this definition.
-
May 1, 2024 | 
jrheum.org | Eric F. Morand |Sarah Jones |S.A. Jones |E.F. Morand
The concept of systemic lupus erythematosus (SLE) as a relapsing and remitting condition is deeply embedded in how clinicians perceive this disease.
-
Mar 10, 2024 | 
nature.com | Eric F. Morand |Yoshiya Tanaka |Dafna D Gladman
AbstractTyrosine kinase 2 (TYK2) is a member of the JAK kinase family of intracellular signalling molecules. By participating in signalling pathways downstream of type I interferons, IL-12, IL-23 and IL-10, TYK2 elicits a distinct set of immune events to JAK1, JAK2 and JAK3. TYK2 polymorphisms have been associated with susceptibility to various rheumatic diseases including systemic lupus erythematosus and dermatomyositis.
-
Feb 5, 2024 | 
nature.com | Steven Lim |Sarah L. Snelgrove |Eric F. Morand |Peter J. Eggenhuizen |Khai L. Loh |Ashraf Broury
AbstractAntigen-specific regulatory T cells (Tregs) suppress pathogenic autoreactivity and are potential therapeutic candidates for autoimmune diseases such as systemic lupus erythematosus (SLE). Lupus nephritis is associated with autoreactivity to the Smith (Sm) autoantigen and the human leucocyte antigen (HLA)-DR15 haplotype; hence, we investigated the potential of Sm-specific Tregs (Sm-Tregs) to suppress disease.
-
Jan 9, 2024 | 
acrjournals.onlinelibrary.wiley.com | Arushi Ramnarain |Christy Liam |Dominique Milea |Eric F. Morand
INTRODUCTION Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease with great heterogeneity in its clinical course and treatment response.
-
Dec 20, 2023 | 
lupus.bmj.com | Laurent Arnaud |Richard A. Furie |Eric F. Morand |Martin Aringer
DiscussionSPOCS is a prospective, observational study designed to analyse clinical outcomes over time of a large, real-world cohort of patients with moderate-to-severe SLE. Overall, this study identified substantial clinical burden in a broadly representative group of patients with moderate-to-severe SLE in a real-world setting, including long disease duration and presence of organ damage in more than half of patients.
-
Aug 1, 2023 | 
rmdopen.bmj.com | Eric F. Morand |Josef S Smolen |Michelle Petri |Yoshiya Tanaka
The safety population in each study included all patients who received ≥1 dose of study drug and who did not discontinue for the reason ‘lost to follow-up’ at the first postbaseline visit. Three integrated data sets were analysed:Placebo-controlled data set: evaluated baricitinib 2 mg and 4 mg vs placebo during the placebo-controlled studies. Extended exposure data set (extended data set): included all patients who were randomised to either baricitinib 2 mg or 4 mg in the phase 2 and 3 studies.
-
Apr 12, 2023 | 
ard.bmj.com | Eric F. Morand |Gabriel Abreu |Richard A. Furie |Raj Tummala
DiscussionThe clinical management of many diseases has been positively impacted by T2T approaches. By demonstrating the association of attainment of a given target state with favourable outcomes, improvements in clinical practice have occurred.
-
Feb 28, 2023 | 
lupus.bmj.com | Sudha Raghunath |Yifat Glikmann-Johnston |Rangi Kandane-Rathnayake |Eric F. Morand
Clinical associations of cognitive dysfunctionOn univariate analysis, increased age, disease duration, SDI and substance use were all associated with reduced performance on cognitive testing; see table 2. Increased premorbid IQ, disease activity according to either time adjusted mean SLEDAI-2K or SLEDAI-2K at the date of assessment, azathioprine use and hypocomplementemia were associated with improved performance on cognitive testing.
